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A B S T R A C T
In order to discuss a role of antibiotics, a 73-year old patient was presented, having an exacerbation of Chronic Ob-
structive Pulmonary Disease (COPD) and to whom amoxicillin/clavulanate antibiotic was prescribed. Literature search
has indicated that antibiotics are recommended for COPD patients in two cases. Firstly, they are recommended in the pa-
tients having an acute exacerbation with increased dyspnoea, sputum volume, and sputum purulence. Common options
usually include amoxicillin, amoxicillin/clavulanate, azithromycin, and doxycycline. Secondly, it is also recommended
for preventive purposes in patients with severe COPD having frequent exacerbations. But, still remain uncertainty on the
antibiotic used in outpatients, having mild or moderate COPD.
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Introduction
A chronic obstructive pulmonary disease (COPD) is
common conditions seen in family medicine (FM) charac-
terized by shortness of breath, cough, and sputum pro-
duction. A prevalence in adult populations is around 5%,
therefore average family doctor (FD) could expect to
have around 50 to 100 patients in his/her practices1. In
2012, it ranked as the third-leading cause of death1. As in
many other chronic diseases, several problems are chal-
lenging the patients and the doctors too. The very often
multiple drag therapy, lasting along the whole life-span is
sometimes difficult for the patients to adhere and adjust
to. But, one of the most challenging is the smoking, im-
portant for ethyology and prognosis of the disease. In
spite of research results, everyday experience with pa-
tients is not promising about smoking cessations2. An-
other, also challenging moment in dealing with COPD
patients, is the frequent exacerbations, usually needing
antibiotic treatment3. Does the patients need to be treat-
ed with antibiotics in every exacerbation and how to
choose the antibiotics is very challenging, especially for
FDs working in a low technological environment. There-
fore, the aim of this case report is to present a patient
case in the light of evidence-based of antibiotic use.
Case Report
My well-known, 73-year old patient, asked me for
home visit because of increased shortness of breath,
raised temperature (37.7 °C), extensive caught and puru-
lent sputum. Six years ago, a COPD was diagnosed,
mainly related to smoking of two boxes of cigarettes for
more than 30 years. At that time, a FEV1 was at the level
of 71%, and a FEV1/FVC of 67%. There were no symp-
toms and signs of a cor pulmonale. He started therapy
with teofilinum, tiatropium and salbutamol if he felt
dyspnoea. He decreased the number of cigarettes, but
never stopped smoking. He also refused a flu vaccination.
Because of the deterioration of hepatic enzymes and be-
cause of the frequent respiratory infections, his therapy
was several times changed, presently taking long acting
b agonist (LABA, Serevent) or long acting anti-musca-
rinic (LAMA, Spiriva) bronchodilators and inhaled cor-
ticosteroid, fluticasone.
Physical examination, performed at home visit, indi-
cated more frequent breading then usually (around 24/
min), bronchial sound all over the chest, wheezing and
prolonged expiration. Puls-oxymeter indicated oxygen
saturation at the level of 93%.
A similar situation is usually happening to him sev-
eral times a year, once he had to be hospitalized because
of pneumonia. Having experience of such situations and
taking into the account his resistance to hospitalization,
amoxicillin with clavulonic acid was prescribed, as well
as salbutamol and oral corticosteroids. It was also recom-
mended to continue with LABA and LAMA, but to stop
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fluticasone inhalation. After two hours, he has made
phone call telling that he felt better, shortness of breath
and cough is also going better. During the next several
days, he completely recovered and continues with his
regular therapy.
Discussion and Conclusion
It is not only this patient who make doctors to think
on the role of antibiotics in the treatment of COPD exac-
erbations, because it can accelerate lung function de-
cline, decrease quality of life, and, when severe, increase
mortality4. Infections cause an estimated 50 to 70% of
COPD exacerbations, therefore the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines
recommend using antibiotics to treat exacerbations in
patients with moderate or severe COPD who have in-
creased dyspnoea, sputum volume, and sputum puru-
lence5. Furthermore, the costs of exacerbation are usu-
ally higher in patients not treated with antibiotic, mainly
because of hospital care; 9.6% of the costs for drugs and
72.9% for hospital care6.
The needs for antibiotic use in COPD exacerbation
were found in the review studies too. WITHDRAWN re-
view shows that in COPD exacerbations with increased
cough and sputum purulence, antibiotics, regardless of
choice, reduce the risk of short-term mortality by 77%,
decrease the risk of treatment failure by 53% and the
risk of sputum purulence by 44%; with a small increase
in the risk of diarrhea. But, they pointed that the results
should be interpreted with caution due to the differences
in patient selection, antibiotic choice, small number of
included trials and lack of control for interventions that
influence outcome, such as use of systemic corticoste-
roids and ventilator support. Nevertheless, this review
supports antibiotics for patients with COPD exacerba-
tions with increased cough and sputum purulence who
are moderately or severely ill7. In recent, Cochrane Data-
base Systematic Review done in 2012, the sixteen trials
with 2068 participants were included; outpatients con-
sidering to have a mild to moderate exacerbation, and in-
patients to have a severe exacerbation and intensive care
unit (ICU) patients to have a very severe exacerbation.
The author’s conclusion should be formulated in a way
that antibiotics for COPD exacerbations showed large
and consistent beneficial effects across outcomes of pa-
tients admitted to an ICU. However, for outpatients and
inpatients the results were inconsistent. The risk for
treatment failure was significantly reduced in both inpa-
tients and outpatients when all trials (1957 to 2012) were
included but not when the analysis for outpatients was
restricted to currently used antibiotics. Also, antibiotics
had no statistically significant effect on mortality and
length of hospital stay in inpatients and almost no data
on patient-reported outcomes exist. These inconsistent
effects call for research into clinical signs and biomar-
kers that help identify patients who benefit from antibi-
otics and patients who experience no effect, and in whom
downsides of antibiotics (side effects, costs and multi-re-
sistance) could be avoided8.
According to other studies as well as to the GOLD
guidelines, the choice of antibiotic is usually based on
doctors’ experience and the local situation5,9,10. Common
options usually include amoxicillin, amoxicillin/clavula-
nate, azithromycin, and doxycycline4,11. In spite of this,
antibiotics’ choice is still under debate. A study done by
Llor and colleagues, provide the evidence that treatment
of ambulatory exacerbations of mild-to-moderate COPD
with amoxicillin/clavulanate is more effective and signifi-
cantly prolongs the time to the next exacerbation com-
pared with placebo4. Blasi and colleagues concluded that
both prulifloxacin and levofloxacin showed efficacy rates
higher than 90% in the treatment of severe COPD pa-
tients with exacerbations of chronic bronchitis, with no
statistically significant differences between the two anti-
biotics12. The similar situation is with levofloxacin ver-
sus cefuroxime13. Looking at those studies, one can ma-
kes a conclusion that if the broad range of antibiotics is
appropriate to use, the choice should be based on side-ef-
fects, easy administration, availability, but also the anti-
biotics’ costs and the availability of public or patients
resources14.
Another question related to the described patients’
case is also about the preventive use of antibiotics. Does
he need to take some antibiotics regularly? Again, Co-
chrane Database Systematic Review from 2013, based on
seven RCTs, involving 3170 patients brought some lights.
They concluded that the continuous prophylactic use of
antibiotics results in a clinically significant benefit in re-
ducing exacerbations in COPD patients. They pointed
out, that all trials of continuous antibiotics used macro-
lides hence the noted benefit applies only to the use of
continuous macrolide antibiotics. The impact of pulsed
antibiotics remains uncertain and requires further re-
search. The trials in this review included patients who
were frequent exacerbates and needed treatment with
antibiotics or systemic steroids, or who were on supple-
mental oxygen. There were also older individuals with a
mean age of 66 years. The authors pointed out, that re-
sults of these trials apply only to the group of patients
who were studied in these trials and may not be general
sable to other groups. Because of concerns about antibi-
otic resistance and specific adverse effects, consideration
of prophylactic antibiotic use should be mindful of the
balance between benefits to individual patients and the
potential harms to society created by antibiotic over-
use15. Similar results come from the study of Han and
colleagues. They have found out that daily azithromycin
decreases acute exacerbations of chronic obstructive pul-
monary disease (AECOPD), but long-term side effects
are unknown16. In UK, the most commonly used long-
-term antibiotics were oxytetracycline, doxycycline, and
penicillin. Azithromycin, erythromycin, and clarithro-
mycin were less frequently used. There was little evi-
dence of the use of rotating courses of antibiotics. It is
also found that men, people aged 50–79 years, non-smok-
ers, and patients with poorer lung function were more
likely to receive long-term antibiotic treatment. But, rel-
M. Rapi}: Exacerbation of Chronic Obstructive Pulmonary Disease, Coll. Antropol. 38 (2014) Suppl. 2: 223–226
224
atively few COPD patients are currently prescribed long-
-term antibiotics in UK17.
Long-term or intermittent antibiotic treatment has
been shown to prevent COPD exacerbations and hospi-
talizations. These effects may be achieved by reducing
bacterial load in the airways in stable state and/or bron-
chial inflammation. Although systemic antibiotics are
likely to remain the core treatment for patients with
moderate to severe exacerbated COPD, inhaled antibiot-
ics may represent a more optimal approach for the treat-
ment and prevention of COPD exacerbations in the fu-
ture17,18. The budget impact analysis demonstrated that
annual hospital savings of 950 million resulting from
fewer exacerbations outweighed additional expenditure
on azithromycin of 595 million, implying that the pre-
vention of COPD exacerbations with azithromycin is a
cost saving strategy in Belgium19.
Although, the aim of this study is to find out the evi-
dence on the role of antibiotics in the exacerbation of
COPD, a role of other treatment options should not be
forgotten. As Aaron pointed out in his review paper, no
obvious benefit has been seen in recent clinical trials of
anti-tumor necrosis factor therapy, anti-leukotriene the-
rapy, intensive chest physiotherapy, or early inpatient
pulmonary rehabilitation for treatment of exacerbations.
By contrast, clinical trials of prevention rather than
acute treatment have shown promising results. Long act-
ing b agonist (LABA) or long acting anti-muscarinic
(LAMA) bronchodilators and inhaled corticosteroid-
-LABA combinations prevent exacerbations in patients
at risk, with relative risk reductions averaging 14–27%
for each of these drugs relative to placebo. Triple therapy
with inhaled corticosteroid-LABA plus LAMA may pro-
vide additional benefit, although study results to date are
heterogeneous and more studies are needed. Pneumonia
is an important complication of treatment with inhaled
corticosteroid-LABA products, and the risk of pneumo-
nia seems to be doubled in patients with COPD who use
fluticasone. The addition of azithromycin to usual COPD
therapy prevents exacerbations, although it may prolong
the Q-T interval and increase the risk of death from car-
diovascular disease in patients prone to arrhythmia. New
potential drugs, including mitogen activated protein
kinase inhibitors, phosphodiesterase 3 inhibitors, and
monoclonal antibodies to the interleukin 1 receptor, offer
additional hope for treatments that may prevent exacer-
bations in the future20.
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EGZACERBACIJA KRONI^NE OPSTRUKTIVNE PLU]NE BOLESTI: ULOGA ANTIBIOTIKA?
S A @ E T A K
Prikazan je primjer 73-godi{njeg pacijenta u egzacerbaciji kroni~ne opstruktivne plu}ne bolest (COPB) kojemu je
propisana antibiotska terapija s namjerom da se prodiskutira uloga antibiotika u egzacerbaciji COPB. Sukladno litera-
turi, primjena antibiotika je po`eljna u dva slu~aja. Prvo, u akutnoj egzacerbaciji, i to naj~e{}e amoxicillin, amoksicilin/
klavulonska kiselina, azitromicin, i doksiciklin. Drugi je slu~aj preventivnog uzimanja, osobito u slu~ajevima te{kih
oblika COPB, s ~estim egzacerbacijama, naj~e{}e makrolida. Me|utim, jo{ uvijek postoji dilema primjene antibiotika
kod blagih i umjerenih oblika bolesti i u uvjetima primarne zdravstvene za{tite. Izgleda da je najoptimalniji indivi-
dualan pristup pacijentu, temeljan na stanju pacijenta i iskustvu lije~nika.
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